MedTrace Logo

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT05003245 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 407

Last updated 2025-03-24

No results posted yet for this study

Summary

this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection

0.05mL solution at a 4-week interval for intravitreal injection

DRUG

Lucentis

0.05mL solution at a 4-week interval for intravitreal injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-05-07
Completion
2024-05-07

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05003245 on ClinicalTrials.gov